

ADURS2022 Speakers Titles/Objectives

Thursday, February 24, 2022

Cynthia Denmark, RPh, Deputy Director, Division of Pharmacy, Center for Medicaid & CHIP Services, Centers for Medicare & Medicaid Services

Title: CMS Medicaid Update 2022

ACPE UAN: 0128-9999-22-001-L04-P

CPE: 1.0 contact hour / Knowledge-based CPE activity

Objectives:

1. Examine trends and innovations used for drug utilization reviews programs across the country.
2. Identify how Medicaid programs can participate in Value Based Purchasing arrangements.
3. Describe the drugs that have mandatory coverage under the Medicaid program.

Friday, February 25, 2022

Steve Liles, PharmD, Senior Director, Industry Relations, Pharmacy Benefit Solutions, Change Healthcare

Title: Drug Approvals of 2021: Clinical, Financial, and Management Implications for Medicaid Programs

ACPE UAN: 0128-9999-22-002-L01-P

CPE: 1.5 contact hour / Knowledge-based CPE activity

Objectives:

1. Identify two newly approved molecular entities or biologics that have the potential to significantly improve clinical outcomes for many Medicaid recipients.
2. Identify two newly approved molecular entities or biologics that have the potential to significantly increase Medicaid drug expenditures.
3. Describe utilization management tools that could be used to optimize the use of the newly approved drugs or biologics.

Donnie Sullivan, RPh, PhD, Clinical Professor of Pharmacy, OH State University College of Pharmacy

Title: Innovative Strategies for Tackling Prescription Drug Diversion

ACPE UAN: 0128-9999-22-003-L04-P

CPE: 1.0 contact hour / Knowledge-based CPE activity

Objectives:

1. Identify current trends in prescription drug diversion.
2. Describe educational, operational, and incentive-based initiatives to change prescribing behavior related to prescription drug diversion.
3. Describe educational, operational, and incentive-based programs to affect patient care provided by pharmacists in high risk-controlled substance prescriptions.

Amanda Kiriakopoulos, PharmD, Account Consultant Pharmacist, Clinical Account Manager, OptumRx, Indiana Medicaid

Title: State Roundtable - State Medicaid Programs (Part 1)

ACPE UAN: 0128-9999-22-004-L04-P

CPE: 1.0 contact hours / Knowledge-based CPE activity

Objectives:

1. Define retroDUR methodologies and processes utilized by State Medicaid Programs and explain how retroDUR impacts State Medicaid patient health and fiscal outcomes.
2. Identify factors that contribute to the successes and challenges of State Medicaid programs medication management initiatives.
3. Describe DUR initiatives based upon the proposal phase, implementation phase, program delivery, and outcome evaluation phase.

Maria M. Lowe, PharmD, BCPS, Director of Pharmaceutical Intelligence, Institute for Clinical and Economic Review

Title: Pipeline Preview 2022

ACPE UAN: 0128-9999-22-005-L04-P

CPE: 1.5 contact hours / Knowledge-based CPE activity

Objectives:

1. Describe recent trends in the FDA approval process.
2. Identify agents in the late-stage pipeline across key therapeutic areas.
3. List the first-time generics expected to hit the market within the next two years.

Cynthia Denmark, RPh, Deputy Director, Division of Pharmacy, Center for Medicaid & CHIP Services, Centers for Medicare & Medicaid Services; **Natalie Browning**, Senior Director of Client Relationships, Bamboo Health

Title: Support Act Section 5042: PDMP Statutory Requirements and Drug Utilization Review

ACPE UAN: 0128-9999-22-006-L03-P

CPE: 1.0 contact hour / Knowledge-based CPE activity

Objectives:

1. Review the complexities associated with State PDMP reporting requirements.
2. Identify a path forward to support State PDMPs compliance with CMS reporting requirements.
3. Describe barriers to CMS Reporting for State PDMPs.

Amanda Kiriakopoulos, PharmD, Account Consultant Pharmacist, Clinical Account Manager, OptumRx, Indiana Medicaid

Title: State Roundtable - State Medicaid Programs (Part 2)

ACPE UAN: 0128-9999-22-007-L04-P

CPE: 1.0 contact hours / Knowledge-based CPE activity

Objectives:

1. Define retroDUR methodologies and processes utilized by State Medicaid Programs and explain how retroDUR impacts State Medicaid patient health and fiscal outcomes.
2. Identify factors that contribute to the successes and challenges of State Medicaid programs medication management initiatives.
3. Describe DUR initiatives based upon the proposal phase, implementation phase, program delivery, and outcome evaluation phase.

Saturday, February 26, 2022

Thomas Frank, PharmD, BCPS, Frank Medical Consulting

Title: Improving Therapeutics Using the Choosing Wisely Program

ACPE UAN: 0128-9999-22-008-L04-P

CPE: 1.0 contact hour / Knowledge-based CPE activity

Objectives:

1. Describe the clinical opportunities to improve diagnostic and drug therapeutics using evidence-based interventions.
2. Explain how to improve cost and value propositions in a wide range of healthcare circumstances.
3. Review healthcare specialty organizations' recommendations for application tips in patients of interest.

Joshua Moore, PharmD, Director of Pharmacy, MO HealthNet, State of Missouri

Title: "Show-Me" the PAD

ACPE UAN: 0128-9999-22-009-L04-P

CPE: 0.5 contact hour / Knowledge-based CPE activity

Objectives:

1. Describe how MO HealthNet processes physician administered drugs for payment.
2. Review how to implement prior authorizations for physician administered drugs.
3. Identify ways to alleviate concerns with managing physician administered drugs.

Jane Gennrich, PharmD, Pharmacy Services Specialist, Idaho Department of Health and Welfare

Title: Idaho Medicaid's Physician Administered Drugs (PAD) Program

ACPE UAN: 0128-9999-22-010-L04-P

CPE: 0.5 contact hour / Knowledge-based CPE activity

Objectives:

1. Describe how to start a prior authorization program for physician administered drugs – begin with newly FDA approved drugs and then gradually review all current PAD drugs.
2. Explain three criteria used to determine whether a physician administered drug should require prior authorization – cost, potential for inappropriate use, claim volume.
3. Examine “dump code” claims periodically (e.g., quarterly) for inappropriate billing – number of claims, dollar amount paid, billing NPI, and whether they should have been billed using a drug-specific code.

Emily Baker, PharmD, BCPS, MBA, MHA, President, NorthStar HealthCare Consulting

Title: Trends in Fraud, Waste, and Abuse

ACPE UAN: 0128-9999-22-011-L04-P

CPE: 1.0 contact hour / Knowledge-based CPE activity

Objectives:

1. List recent trends in fraud, waste, and abuse.
2. Describe implications of fraud, waste, and abuse on Medicaid programs.
3. Detail efforts to reduce fraud, waste, and abuse.

Lisa Correll, PharmD, Clinical Account Manager, Magellan Medicaid Administration

Title: “To B, or not to B...340B, that is”

ACPE UAN: 0128-9999-22-012-L03-P

CPE: 0.5 contact hour / Knowledge-based CPE activity

Objectives:

1. Review the approach that leads the State to their 340B solution.
2. Outline the process used to implement the program.
3. Identify next steps (340B medical claims).

Raymond McIntire, DPH, Director of Pharmacy Operations, TennCare

Title: Tennessee's Implementation of a 340B Pharmacy and Medical Claims Solution

ACPE UAN: 0128-9999-22-013-L03-P

CPE: 0.5 contact hour / Knowledge-based CPE activity

Objectives:

1. Describe the use of the CMS' Drug Data Reporting (DDR) files to prepare an estimated 340B Ceiling Price file to use for claims analysis and provider reimbursement.
2. Explain how to organize data to measure whether the Agency is overpaying claims to 340B Covered Entities.
3. Review the use of CMS-suggested modifiers used in submitting 340B physician administered medical claims.

Amanda Kiriakopoulos, PharmD, Account Consultant Pharmacist, Clinical Account Manager, OptumRx, Indiana Medicaid

Title: State Roundtable - State Medicaid Programs (Part 3)

ACPE UAN: 0128-9999-22-014-L04-P

CPE: 1.0 contact hours / Knowledge-based CPE activity

Objectives:

1. Define retroDUR methodologies and processes utilized by State Medicaid Programs and explain how retroDUR impacts State Medicaid patient health and fiscal outcomes.
2. Identify factors that contribute to the successes and challenges of State Medicaid programs medication management initiatives.
3. Describe DUR initiatives based upon the proposal phase, implementation phase, program delivery, and outcome evaluation phase.



The **2022 ADURS Symposium** is designed for pharmacists specializing in medication utilization within State Medicaid programs and is supported by the American Drug Utilization Review Society (ADURS) and the Nebraska Pharmacy Association (NPA). NPA is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Credit for courses must be earned by the participant. Participants will earn **13.0 contact hours** of continuing pharmacy education (CPE) credits for attendance of the entire symposium.

To earn CPE credits, the participant must complete an on-line educational evaluation form for each CPE session they attend within 15 days from the end of the symposium. The evaluation will collect birthdates (MMDD) and NABP e-Profile ID numbers (to receive CPE credits, the attendee must have an NABP e-Profile ID number). For more information about NABP e-Profile IDs, please see <https://nabp.pharmacy/programs/cpe-monitor/>. ACPE CPE numbers and speaker objectives can be found in the program schedule. **CPE credits will be sent to your NABP e-Profile within 45 days of the program date.** For questions about CPE credits, please email Loralyn Joyce at ljoyce.adurs@gmail.com.